KOD News and Press, Kodiak Sciences Inc From 05/30/22

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

Kodiak Sciences to Present at the Jefferies Global Healthcare Conference PR Newswire PALO ALTO, Calif. , May 27, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative t...

Kodiak Sciences (NASDAQ:KOD) rose 13%, Thursday, after 10% owner of the company Baker Bros. Advisors increased its indirect stakes in the company. As per the SEC filing dated May 16, Baker Bros. Advisors has bought 456,690 shares at the price range of $5.45 - $6.06 each, amounting to ~$2...

Kodiak Sciences (NASDAQ:KOD), which develops therapies for retinal diseases, and Swiss manufacturing company Lonza announced the opening of a new bioconjugation facility within Lonza's Visp, Switzerland manufacturing complex. The facility will support the scaled manufacturing of KOD's lead th...

Indaptus Therapeutics (INDP) +22% on FDA nod to begin phase 1 trial of Decoy20 for solid tumors. Zealand Pharma (ZEAL) +19% announces positive results from phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism.  CBAK Energy Technology (CBAT)&#...

Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases PR Newswire Purpose-built bioconjugation facility in Lonza's Ibex ® Dedicate B...

Results from the BEACON study, which is using KSI-301 for the treatment of patients with retinal vein occlusion, are expected by Q3 of 2022. The global retinal vein occlusion market is estimated to be worth $25.66 billion by 2028. Additional trial readouts using new dosing schedul...

Kodiak Sciences press release (NASDAQ:KOD): Q1 GAAP EPS of -$1.83 misses by $0.27. Cash and cash equivalents of $671.7M. "We continued progressing our pipeline product candidates KSI-501 and KSI-601. KSI-501 is our dual inhibitor antibody biopolymer conjugate targeting both VEGF (VE...

Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , May 10, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and com...

ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT, CAPL, CARA, CARG, CHMI, CLAR, CLOV, CNNE, CSTL, OTCPK:CURLF, DDD, DHT, DNB, ENTA, EQH, EVBG, FCRD, FF, FGEN, FLL, ...